Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
NCT06462014 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 507
Last updated 2025-12-11
Summary
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
Conditions
Interventions
- DRUG
-
Relugolix
relugolix
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-06-19
- Primary Completion
- 2024-12-13
- Completion
- 2024-12-13
Countries
- United States
Study Locations
More Related Trials
-
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
NCT05467176 ·Status: ACTIVE_NOT_RECRUITING
-
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT05053152 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT05765500 ·Status: RECRUITING ·Phase: PHASE2
-
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
NCT06330805 ·Status: RECRUITING ·Phase: PHASE2
-
Rucaparib in Nonmetastatic prOstAte With BRCAness
NCT03533946 ·Status: TERMINATED ·Phase: PHASE2
-
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
NCT06111781 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
NCT05679388 ·Status: TERMINATED ·Phase: PHASE1
-
RElugolix VErsus LeUprolide Cardiac Trial
NCT05320406 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
NCT04301414 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
NCT06499870 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
NCT00828308 ·Status: COMPLETED ·Phase: PHASE2
-
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
NCT06650579 ·Status: RECRUITING ·Phase: PHASE3
-
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
NCT04114825 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
NCT06204302 ·Status: COMPLETED
-
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
NCT07025369 ·Status: RECRUITING ·Phase: PHASE2
-
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer
NCT02499848 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia
NCT01320735 ·Status: COMPLETED
-
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
NCT02083185 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
NCT00638378 ·Status: TERMINATED ·Phase: PHASE2
-
Degarelix Before Radical Prostatectomy
NCT01852864 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
NCT06631521 ·Status: RECRUITING ·Phase: PHASE1
-
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
NCT02506114 ·Status: TERMINATED ·Phase: PHASE2
-
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
NCT00215683 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
NCT03080116 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2